Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Trial For Cryptococcal Meningitis
NCT06666322Phase 3Recruiting
- Start
- May 2025
- Primary completion
- Apr 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oteseconazole and turletricin in cryptococcal meningitis (5 arms). Primary endpoints: Rate of cerebrospinal fluid (CSF) Cryptococcus clearance (Early Fungicidal Activity) at 2 weeks and All-cause mortality at 2 weeks. Started May 2025; status: recruiting.
02
Drugs
oteseconazoleturletricin
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on NCT06666322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666322.